{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:11:38Z","timestamp":1777356698675,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyowa Kirin International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-022-01006-7","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T16:02:50Z","timestamp":1659628970000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7732","authenticated-orcid":false,"given":"Suzanne","family":"Jan de Beur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-2601","authenticated-orcid":false,"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-6768","authenticated-orcid":false,"given":"Thomas","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-1265","authenticated-orcid":false,"given":"Hae Il","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-8258","authenticated-orcid":false,"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-4117","authenticated-orcid":false,"given":"Rachel K.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2631","authenticated-orcid":false,"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-3467","authenticated-orcid":false,"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-6723","authenticated-orcid":false,"given":"Steven W.","family":"Ing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-5679","authenticated-orcid":false,"given":"Karl","family":"Insogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-5372","authenticated-orcid":false,"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0048","authenticated-orcid":false,"given":"Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4226","authenticated-orcid":false,"given":"Peter","family":"Kamenicky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-4405","authenticated-orcid":false,"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-2581","authenticated-orcid":false,"given":"Robin H.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-0127","authenticated-orcid":false,"given":"Farzana","family":"Perwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pisit","family":"Pitukcheewanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-6898","authenticated-orcid":false,"given":"Anthony","family":"Portale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-7586","authenticated-orcid":false,"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9117-3534","authenticated-orcid":false,"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-2288","authenticated-orcid":false,"given":"Thomas J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-186X","authenticated-orcid":false,"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-6349","authenticated-orcid":false,"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-9491","authenticated-orcid":false,"given":"Annabel","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"issue":"7","key":"1006_CR1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26(7):1381\u20131388. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1006_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, Sechi A et al (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41(5):865\u2013876. https:\/\/doi.org\/10.1007\/s10545-018-0147-6","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1006_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","volume":"171","author":"DC Hardy","year":"1989","unstructured":"Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP (1989) X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology 171(2):403\u2013414. https:\/\/doi.org\/10.1148\/radiology.171.2.2539609","journal-title":"Radiology"},{"issue":"6","key":"1006_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","volume":"68","author":"IR Reid","year":"1989","unstructured":"Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP (1989) X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 68(6):336\u2013352","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"1006_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, Theodore-Oklota C et al (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3(7):1321\u20131334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocr Soc"},{"issue":"2","key":"1006_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","volume":"37","author":"N Ferizovic","year":"2020","unstructured":"Ferizovic N, Marshall J, Williams AE, Mughal MZ, Shaw N, Mak C, Gardiner O et al (2020) Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal. Adv Ther 37(2):770\u2013784. https:\/\/doi.org\/10.1007\/s12325-019-01193-0","journal-title":"Adv Ther"},{"issue":"7","key":"1006_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"1006_CR8","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, Weber T et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33(8):1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1006_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R et al (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105(3):271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"1006_CR10","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M et al (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100(7):2565\u20132573. https:\/\/doi.org\/10.1210\/jc.2015-1551","journal-title":"J Clin Endocrinol Metab"},{"key":"1006_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK et al (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714","journal-title":"RMD Open"},{"key":"1006_CR12","unstructured":"Cleeland CS (2009) The Brief Pain Inventory User Guide. https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/BPI_UserGuide.pdf"},{"key":"1006_CR13","doi-asserted-by":"crossref","unstructured":"Skrinar A, Theodore-Oklota C, Bonner N, Arbuckle R, Williams A, Nixon A (eds) (2019) Confirmatory psychometric validation of the Brief Pain Inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH). ISPOR; Copenhagen","DOI":"10.1016\/j.jval.2019.09.2483"},{"key":"1006_CR14","unstructured":"Bellamy N (2012) WOMAC osteoarthritis index user guide. Version X. . Brisbance"},{"issue":"suppl 3","key":"1006_CR15","first-page":"S870","volume":"22","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Theodore-Oklota C, Bonner N, Arbuckle R, Williams A, Nixon A (2019) Confirmatory psychometric validation of the Western Ontario and McMaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH). Value Health 22(suppl 3):S870","journal-title":"Value Health"},{"issue":"5","key":"1006_CR16","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186\u20131196","journal-title":"Cancer"},{"key":"1006_CR17","doi-asserted-by":"crossref","unstructured":"Nixon A, Williams A, Theodore-Oklota C (eds) Psychometric validation of the Brief Fatigue Inventory (BFI) in adult x-linked hypophosphatemia (XLH). ISPOR; 2020; Orlando","DOI":"10.1016\/j.jval.2020.04.1301"},{"key":"1006_CR18","unstructured":"ATS. ATS Statement: Guidelines for the Six-Minute Walk Test 2002. https:\/\/www.thoracic.org\/statements\/resources\/pfet\/sixminute.pdf"},{"key":"1006_CR19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab739","author":"MK Javaid","year":"2021","unstructured":"Javaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K, Imel EA (2021) Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgab739","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1006_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0197-2456(90)90030-6","volume":"11","author":"CE Davis","year":"1990","unstructured":"Davis CE, Leffingwell DP (1990) Empirical Bayes estimates of subgroup effects in clinical trials. Control Clin Trials 11(1):37\u201342. https:\/\/doi.org\/10.1016\/0197-2456(90)90030-6","journal-title":"Control Clin Trials"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-022-01006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-022-01006-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-022-01006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T16:06:12Z","timestamp":1664985972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-022-01006-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1007\/s00223-022-01006-7","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors served as clinical investigators for one or more studies, including this trial, sponsored by Ultragenyx Pharmaceutical Inc. in partnership with Kyowa Kirin International plc: MLB, SJdB, KB, TOC, HIC, MC-S, RKC, RE, YI, EAI, KI, SI, NI, MKJ, PK, RK, TK, RHL, FP, PP, AAP, SHR, HT, TJW, H-WY, YT. SJdB, TOC, EAI, RHL, FP, AAP, and TJW have also received honoraria from Ultragenyx Pharmaceutical Inc. for serving as an advisory board member or for delivering lectures and AAP and TJW have received travel reimbursement. TOC, YI, MJK, RK, TK, and YT have received honoraria for serving as an advisory board member or for speaker fees from Kyowa Kirin International plc. During the past 3\u00a0years, the following authors have received grants outside of the submitted work: RE from Alexion Pharmaceuticals, Amgen, Immunodiagnostic Systems Holdings plc, Nittobo Medical Co., Ltd., and Roche; SI from Alexion Pharmaceuticals, Radius Health, and Takeda Pharmaceutical Company; NI, MJK, and RHL from Kyowa Kirin International plc; TK from Teijin Pharma; PP from Ultragenyx Pharmaceutical Inc.; and SHR from Amgen, UCB, and AstraZeneca. PP is currently an employee of Ascendis Pharma Inc. AW is an employee of Kyowa Kirin International plc and WS is an employee of Kyowa Kirin Pharmaceutical Development, Inc. AN and MN are employees of Chilli Consultancy and have received consultancy fees from Kyowa Kirin International plc to support the development of this manuscript and for projects outside this submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As stated in the abstract, this study is a post hoc subgroup analysis from an approved phase 3 Clinical Trial\n(ClinicalTrials.gov NCT02526160) for which informed consent was obtained from all participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent statements"}}]}}